- Home
- BREA vs HOTH Comparison
BREA vs HOTH Comparison
Compare BREA & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BREA
- HOTH
- Stock Information
- Founded
- BREA 2022
- HOTH 2017
- Country
- BREA Ireland
- HOTH United States
- Employees
- BREA N/A
- HOTH N/A
- Industry
- BREA Services-Misc. Amusement & Recreation
- HOTH Biotechnology: Pharmaceutical Preparations
- Sector
- BREA Consumer Discretionary
- HOTH Health Care
- Exchange
- BREA Nasdaq
- HOTH Nasdaq
- Market Cap
- BREA 16.1M
- HOTH 15.6M
- IPO Year
- BREA 2023
- HOTH 2019
- Fundamental
- Price
- BREA $6.55
- HOTH $1.27
- Analyst Decision
- BREA
- HOTH Strong Buy
- Analyst Count
- BREA 0
- HOTH 3
- Target Price
- BREA N/A
- HOTH $4.00
- AVG Volume (30 Days)
- BREA 12.3K
- HOTH 301.7K
- Earning Date
- BREA 01-01-0001
- HOTH 05-12-2025
- Dividend Yield
- BREA N/A
- HOTH N/A
- EPS Growth
- BREA N/A
- HOTH N/A
- EPS
- BREA N/A
- HOTH N/A
- Revenue
- BREA $2,988,009.00
- HOTH N/A
- Revenue This Year
- BREA N/A
- HOTH N/A
- Revenue Next Year
- BREA N/A
- HOTH N/A
- P/E Ratio
- BREA N/A
- HOTH N/A
- Revenue Growth
- BREA 151.51
- HOTH N/A
- 52 Week Low
- BREA $5.00
- HOTH $0.59
- 52 Week High
- BREA $19.50
- HOTH $3.80
- Technical
- Relative Strength Index (RSI)
- BREA 48.35
- HOTH 49.03
- Support Level
- BREA $6.14
- HOTH $1.26
- Resistance Level
- BREA $6.75
- HOTH $1.40
- Average True Range (ATR)
- BREA 0.41
- HOTH 0.10
- MACD
- BREA 0.01
- HOTH -0.02
- Stochastic Oscillator
- BREA 41.84
- HOTH 48.13
About BREA Brera Holdings PLC
Brera Holdings PLC focused on expanding social impact football by developing a international portfolio of emerging football clubs with increased opportunities to earn tournament prizes, gain sponsorships, and provide other professional football and related consulting services.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).